ACM
EBS icon

Aviance Capital Management’s Emergent Biosolutions EBS Stock Holding History

Aviance Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1K Sell
24
-2,941
-99% -$173K ﹤0.01% 224
2018
Q4 		$176K Sell
2,965
-1,932
-39% -$125K 0.02% 159
2018
Q3 		$322K Buy
+4,897
New +$286K 0.03% 136

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aviance Capital Management's EBS Position: Q1 2019 in Review

Aviance Capital Management reduced its Emergent Biosolutions (EBS) stake by 99% in Q1 2019, selling an estimated $173K and leaving 24 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #224.

Aviance Capital Management first reported a position in EBS in Q3 2018 and has held it in 3 quarters since. The position peaked at $322K in Q3 2018. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

  • Aviance Capital Management held 24 shares of Emergent Biosolutions worth $1K as of Q1 2019.
  • Aviance Capital Management sold 2,941 Emergent Biosolutions shares in Q1 2019, an estimated $173K.
  • Emergent Biosolutions made up ﹤0.01% of Aviance Capital Management's portfolio in Q1 2019, its #224 holding.
  • Aviance Capital Management first reported a position in Emergent Biosolutions in Q3 2018 and has held it in 3 quarters since.
  • Aviance Capital Management's Emergent Biosolutions position peaked at $322K in Q3 2018.
  • 272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on Aviance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.